Healthcare Industry News: Mobetron
News Release - July 12, 2006
IOERT Shown to be Effective in Treating Pancreatic CancerSUNNYVALE, Calif.--(HSMN NewsFeed)--July 12, 2006--IntraOp Medical Corporation (OTCBB: IOPM ), the developer of a mobile electron-beam accelerator for delivering intraoperative electron radiation therapy (IOERT), announces that a recently published report of a study group of the Italian Association of Radiotherapy (AIRO) concluded that IOERT treatment markedly improves clinical outcomes for patients with pancreatic cancer. Pancreatic cancer is one of the most deadly forms of cancer, claiming the lives of over 31,000 Americans each year.
For resectable (operable) tumors, the AIRO study group report concluded that IOERT provided increased local control to as many of 80% of the patients. This compares favorably to about a 33% local control rate for patients who do not receive IOERT. In pancreatic cancer, local control is usually associated with a reduction or elimination of pain and less hospitalization. Furthermore, the five year survival rate of patients treated with IOERT reviewed in their analysis ranged from 23 to 33%. The AIRO analysis is also supported by a recent U.S. publication that showed survival rates as high as 37% for patients with operable tumors treated with IOERT, compared to, at best, 20% for patients who do not receive IOERT.
For unresectable (inoperable) pancreatic cancer, however, survival is less likely -- patients usually succumb to the disease within a year, and few survive past three years. With IOERT though, there are some long-term survivors. A recent U.S. study of more than 150 unresectable pancreatic patients treated with IOERT showed that a few patients survived as long as eight years. Furthermore, other studies show that even those patients with inoperable tumors still experience a dramatic increase in local control after receiving IOERT. In one Japanese study, patients with inoperable pancreatic cancer who received IOERT had a significantly longer hospital-free survival than those who did not. In this study, IOERT not only improved the patient's quality-of-life, it reduced the cost of their medical treatment as well.
"These studies validate the valuable role that IOERT can play in treating patients with both the resectable and unresectable pancreatic cancer. Meanwhile, other recent studies have shown similar gains for IOERT in the treatment of locally advanced head and neck cancers, advanced rectal cancer, and early-stage breast cancer," said Dr. Donald Goer, Chief Executive Officer of IntraOp. "As the manufacturer of the Mobetron system, an electron-beam accelerator designed exclusively for IOERT, each of these studies marks a significant milestone for our Company."
About IntraOp Medical Corporation
IntraOp Medical Corporation improves the quality of life for cancer patients through the development, manufacturing and sales of its proprietary Mobetron system. The Mobetron is a mobile electron-beam accelerator designed exclusively for intraoperative electron radiation therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery. The system makes IOERT widely available, cost effective, and simple to deliver because it is easily transportable between operating rooms and does not require a cost-prohibitive, radiation shielded surgical suite. The system is FDA-certified for sale in the United States and has received the equivalent foreign approvals: CE Mark in Europe, JIS in Japan and SDA in China. IntraOp Medical Corporation is based in Sunnyvale, California. For more information please visit www.intraopmedical.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.